Yunkang Group Limited

Equities

2325

KYG9889T1067

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. 04:08:32 2024-09-20 am EDT 5-day change 1st Jan Change
8.260 HKD -1.31% Intraday chart for Yunkang Group Limited +0.73% -32.85%
LockThis article is reserved for members
To unlock the article, REGISTER!
Vous êtes déja client ? Log In
Yunkang Group Swings to Loss in H1 as Revenue Falls 20% MT
Yunkang Group Limited Reports Earnings Results for the Half Year Ended June 30, 2024 CI
Yunkang Group Expects Swing to Loss in H1 MT
Yunkang Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2024 CI
Yunkang Group Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
Yunkang Group Limited Announces Executive Changes CI
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2023, Payable on 28 August 2024 CI
Yunkang Group Sees Potential in Outsourcing Lab Testing Services for China's Public Hospitals MT
Everbest Machinery Industry to Set Up 30 Million Yuan Joint Venture MT
Yunkang Swings to Loss in 2023; Recommends Dividend MT
Yunkang Group Limited Proposes Final Cash Dividend for the Financial Year End 31 December 2023 CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yunkang Group Expects a Loss of Up to 130 Million Yuan for Full Year 2023 MT
Yunkang Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Yunkang Group's H1 Attributable Profit Plunges on Lower Revenue MT
Yunkang Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yunkang Group Limited Announces Director Changes CI
Yunkang's Profit to Drop Up to 83% in H1 MT
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022, Payable on August 25, 2023 CI
Yunkang Group Limited Approves Final Dividend for the Year Ended December 31, 2022 CI
Alibaba Names Successors to Chairman & CEO MT
Certain Ordinary Shares of Yunkang Group Limited are subject to a Lock-Up Agreement Ending on 17-MAY-2023. CI
Over 200,000 Firms Want to Test Alibaba's AI Chatbot MT
Yunkang Group Limited Declares Final Dividend for the Year Ended 31 December 2022 CI
Yunkang Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart Yunkang Group Limited
More charts
Logo Yunkang Group Limited
Yunkang Group Ltd is an investment holding company primarily engaged in the provision of diagnosis testing services. The Company’s service portfolio mainly includes three services. The diagnostic outsourcing services engages in the provision of diagnostic outsourcing services to hospitals, other medical institutions and public health institutions. The diagnostic testing services for medical institution alliances engages in assisting hospitals to establish on-site diagnostic centers through joint collaboration in main disease areas such as infectious diseases, reproductive health, genetic diseases and pathology, and the provision of comprehensive solutions including testing technologies, professional technicians and others to hospitals. The diagnostic testing services for non-medical institutions engages in the provision of personalized diagnostic testing, medical report consultation services and hospital referral services. The Company conducts its business in the domestic market.
Employees
1,459
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.589CNY
Average target price
12.08CNY
Spread / Average Target
+59.14%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2325 Stock
  4. News Yunkang Group Limited
  5. Yunkang Group Expects Swing to Loss in H1